Skip to main
ACON
ACON logo

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc. has raised its FY24 EPS estimate to $(0.79) from $(0.89), indicating a positive trend due to lower expenses, which highlights effective cost management efforts. The company's strategic partnership with ATEC, a significant player in the spine implant industry, is expected to enhance access to key opinion leaders and increase awareness of Aclarion's clinical technology, potentially driving revenue growth. Additionally, Aclarion's recent Q2 FY 2024 performance, where it reported an EPS of $(0.15), suggest improving financial metrics that could foster increased payer acceptance and market traction for its Nociscan platform.

Bears say

Aclarion Inc's financial outlook is negatively impacted by significantly lower-than-expected revenue performance, with quarterly revenues of $11,100 representing a 36% year-over-year decline, falling short of the forecasted $29,000. Additionally, the company continues to experience pre-commercial revenue levels, reporting $14,100 and reflecting a 24% year-over-year decrease, which indicates challenges in the market penetration of its Nociscan product. Coupled with substantial risks related to liquidity, regulatory approvals, and competitive pressures, Aclarion faces substantial hurdles in achieving sustainable growth, contributing to a bleak outlook for its financial stability.

Aclarion Inc (ACON) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.